The Road to Readiness: Commentary on the Journey of a Zoonotic H5 Influenza Vaccine Strain Update
Learnings from the development of this vaccine may help to improve pandemic readiness in the future.
New roadmap towards phasing out animal testing for chemical safety assessments in the EU
Only chemical pharmaceuticals come under the scope of the new proposals.
HaDEA: Health Technology Assessment - new opportunity to apply for Joint Scientific Consultations (JSCs)
The request submission period is open from 3 June - 1 July 2026 to developers of both medicinal product and medical devices.
EU Ministers agree negotiating position on Biotech Act I directive
Plus additional updates related to the new Biotech Act.
Comparative Effectiveness of High-Dose and Standard-Dose Influenza Vaccines for Hospitalisation and Mortality in Adults Aged 65 and Older: An Updated Systematic Review and Meta-Analysis
High-dose inactivated influenza vaccine (HD-IV) provides superior protection compared with SD-IV against P&I and all-cause hospitalisation in older adults, with the greatest benefits among younger seniors and those without cardiovascular disease.
Adjuvanted vs High-Dose Influenza Vaccines in Older US Adults
A Cluster Randomized Crossover Study
Immunogenicity and safety of recombinant influenza vaccine versus standard inactivated influenza vaccine in children aged 3 to 8 years: results from a phase III randomised study
Participants aged 3–8 years were randomised in a 1:1 ratio to receive the quadrivalent recombinant influenza vaccine (RIV4) or quadrivalent inactivated influenza vaccine (IIV4).
(Updated) EU recommendations for 2026/2027 seasonal flu vaccine composition
This news announcement includes the information from the EU recommendation for the seasonal influenza vaccine composition for the season 2026/2027 which was amended on two occasions: subsequent to CHMP adoption on 5 May 2026 and on 21 May 2026.
